GENETIC TESTING & HEALTHY LIFESTYLE BLOG

Pathway Genomics Corporation Raises Over $40 Million In Series E Financing

Posted on 01/05/2016 in Editorial, News, Press Releases

SAN DIEGO, CA – January 5, 2016 – Pathway Genomics Corporation, a global precision medicine company with mobile health solutions, today announced it has successfully raised over $40 million in a Series E financing.

This brings the total investment into Pathway Genomics to over $130 million. Investors in this round of funding include IBM Watson, Pathway’s partner in the development of a mobile health application using artificial intelligence to provide personalized health and wellness guidance.

Additional Series E investments will be completed in the first quarter of 2016. This investment will enable the company to expand their presence in the United States and beyond the 40 countries it currently serves internationally, capturing a growing share of the $38 billion global genomics market.

“I’m proud that Pathway is now recognized as a pioneer in the genetic testing industry known for providing affordable and clinically actionable tests not just in the US, but in many countries that don’t have access to this type of advanced genetic testing. This capital will allow us to continue to expand and validate the tests we offer, grow our sales force, and invest in cutting edge technology for our CAP- and CLIA-accredited laboratories,” said Jim Plante, Founder and CEO of Pathway Genomics.

About Pathway Genomics Corporation

Founded in 2008, Pathway Genomics has rapidly become a leader in the commercial healthcare industry. Pathway Genomics’ success lies in its commitment to deliver innovative healthcare solutions. The company’s program with IBM Watson is the first of its kind. The program is a smartphone app that merges artificial intelligence and deep learning with personal genetic information. The app provides users with personalized health and wellness information based on the individual’s health history.

Based in San Diego, the company’s CLIA and CAP accredited clinical laboratory provides physicians and their patients in more than 40 different countries with actionable and accurate precision healthcare information to improve, or maintain, health and wellness. Pathway Genomics’ testing services cover a variety of conditions including cancer risk, cardiac health, inherited diseases, nutrition and exercise response, as well as drug response for specific medications including those used in pain management and mental health. For more about Pathway Genomics, visit www.pathway.com or follow us on Twitter, LinkedIn and Facebook.

 

Pathway Genomics Investor Relations:
Kamal Adawi - CFO
(858) 900-3002
Kamal.Adawi@Pathway.com

Pathway Genomics Debuts First Genomic Wellness App Powered by IBM Watson

Posted on 01/07/2016 in Editorial, News, Press Releases

Pathway Genomics Debuts First Genomic Wellness App Powered by IBM Watson

Alpha Release of OME™ Incorporates Genetics and other Data for Personalized Wellness Recommendations

LAS VEGAS 7 January 2016  Pathway Genomics and IBM (NYSE: IBM) today unveiled at the Digital Health Summit at CES 2016 the closed-alpha release of Pathway Genomics OME™ app, powered by Watson. The Pathway Genomics OME app merges cognitive computing and deep learning with precision medicine and genetics to enable Pathway Genomics to provide consumers with personalized wellness information.

This alpha version of the app incorporates information from Pathway’s “FIT” Test — a wellness-based diet, exercise, and metabolism report compiled with information from the users unique genetic traits, as well as their health habits, data from GPS and wearable health monitors in addition to information from the users Apple HealthKit. Future versions of Pathway’s OME will enable users to opt-in to include electronic health records, insurance information, and additional datasets that will enable OME to provide precise and actionable wellness recommendations.

For example, a user might have genetic variants responsible for metabolizing fats or for feeling sated (full stomach). OME would then consider this information when providing genetically optimal diet plans or even restaurant and menu recommendations. Studies show that users who follow a genetically informed diet can lose significantly more weight that those who follow a “one size fits all” type of plan.

According to Allied Market Research, the bioinformatics market, which includes genetics, is expected to grow to $12.86 billion by 2020; and the even larger mHealth market will grow to $59.1 billion.

“With access to health information via mobile internet, today’s consumers are taking charge of their health and well being more than ever before. But at the same time they are overwhelmed with understanding and interpreting the massive amounts of information that specifically impacts their health and well-being,” said Michael Nova, MD, Chief Innovation Officer, Pathway Genomics. “With Watson cognitive computing leveraged by our technology we are able to deliver real-time, highly personalized insights to empower people to change unhealthy behaviors, allowing them to live healthier lives in ways we never thought possible. Users will have an easy to use side-kick that can do the work of sorting through and make sense of the data that will help them to lead healthier lives.”

To collect relevant genetic data, after approval by a licensed MD, Pathway Genomics will mail the user a saliva DNA collection kit. Then, Pathway will work with additional clinicians and scientists to conduct the Pathway Fit genetic test. The Pathway Fit test specifically looks at 75 genes that focus on phenotypes like diet, exercise, lipids, and sugar metabolism.

Pathway’s OME app then delivers personalized wellness insights to the user based on Pathway Genomics’ proprietary analytics of the findings from the genetic test and other user data combined with Watson cognitive computing technology, intelligent machine learning, and a corpus of health and wellness information. Through Watson APIs, the Pathway app leverages Watson’s natural language processing technology and content in the form of health and wellness information.

“We know that genetics play an important role in each person’s individual health, yet there has been limited access to services and solutions that apply genetics to behaviors that enable day-to-day wellness, ” said Kyu Rhee, MD, Chief Health Officer, IBM Watson Health." Pathway Genomics is the first to innovate both the specific genetic test and a Watson-powered mobile app to help individuals get insights from the data."

In January 2014, the Watson Group announced to advance new cognitive computing capabilities. IBM is investing $100 million to spur innovation for entrepreneurial organizations – ranging from start-ups and VC-backed companies to established players – who, like Pathway Genomics, are collectively bringing forward a new generation of apps and solutions infused with Watson's cognitive computing capabilities.

About Pathway Genomics

Founded in late 2008, Pathway Genomics has rapidly become a leader in the commercial healthcare industry. Pathway Genomics’ success lies in its commitment to deliver innovative healthcare solutions. The company’s program with IBM Watson is the first of its kind, and is a smartphone app that merges artificial intelligence and deep learning with personal genetic information. The app provides users with personalized health and wellness knowledge based on the individual’s health history.

Based in San Diego, the company’s CLIA and CAP accredited clinical laboratory provides physicians and their patients in more than 40 different countries with actionable and accurate precision healthcare information to improve, or maintain, health and wellness. Pathway Genomics’ testing services cover a variety of conditions including cancer risk, cardiac health, inherited diseases, nutrition and exercise response, as well as drug response for specific medications including those used in pain management and mental health. For more about Pathway Genomics, visit www.pathway.com or follow us on Twitter, LinkedIn and Facebook.

For more info about Pathway Genomics, visit www.Pathway.com

 

About IBM Watson

Pioneering a New Era of Computing Watson is the first open cognitive computing technology platform and represents a new era in computing where systems understand the world in the way that humans do: through senses, learning, and experience. Watson continuously learns, gaining in value and knowledge over time, from previous interactions. With the help of Watson, organizations are harnessing the power of cognitive computing to transform industries, help professionals do their jobs better, and solve important challenges.

To advance Watson, IBM has two dedicated business units: Watson, established for the development of cloud-delivered cognitive computing technologies that represent the commercialization of "artificial intelligence" or "AI" across a variety of industries, and Watson Health, dedicated to improving the ability of doctors, researchers and insurers and other related health organizations to surface new insights from data to and deliver personalized healthcare.

For more information on IBM Watson, visit: ibm.com/Watson and ibm.com/press/watson

Follow Watson on Facebook and see Watson on YouTube and Flickr.

Pathway Genomics Announces Definitive Settlement With United States

Posted on 12/30/2015 in News, Press Releases

Pathway Genomics has reached a settlement with the United States Department of Justice. Pathway admits no wrongdoing as part of the settlement and is neither an admission of liability or wrongdoing by the Company, nor a concession by the United States that its claims are not well founded.

Pathway has fully cooperated with the inquiry and was not required to enter into a corporate integrity agreement. We now consider this matter closed. By resolving this issue we can stay focused on our growing business and avoid the time and expense of a potentially lengthy litigation process.

Although Pathway may debate some of the merits of the DOJ's allegations, we recognize and respect the government's responsibility to regulate industry practices. We continue to offer our full array of advanced genetic tests that empowers physicians and patients with accurate and actionable information that allows them to live better and healthier lives.

Media contact:

PR@pathway.com

Meet our new Registered Dietitian — Christina Galiatsatos, RD

Posted on 11/05/2015 in Blog Post

Christina GaliatsatosWe welcome aboard our new registered dietitian, Christina Galiatsatos, to the Pathway Genomics team! Christina is committed to sharing her passion for healthy eating towards optimal health and creating an enjoyable experience for all. She has spent her career in the treatment of weight management, disordered eating patterns, sports nutrition, and disease prevention using an individualized approach. Christina earned a Bachelor’s degree in both Nutrition Sciences and Culinary Arts from Johnson and Wales University in Rhode Island and is also certified in Adult Weight Management. Also, she completed her dietetic internship specializing in Corporate Wellness in which she has instituted in most workplaces. She has been influential in developing nutrition programs in various facilities and the programs thrived under her leadership. Christina's passion for contributing to the process of optimal health is obvious and can be experienced in every aspect of her care. Christina continues to work with patients in nurturing a healthy, nourishing, and balanced relationship with food and exercise. She is passionate about enhancing the eating experience and works to encourage each of her patients on how to transform their lifestyles towards integration of healthy eating and regular exercise. As a former aerobics instructor, Christina can certainly offer suggestions to patients on various exercise regimens. Her culinary background also allows her to support patient's to explore their creativity using various cooking techniques and enables them to incorporate variety.

Pathway Genomics’ Response to FDA Letter on CancerIntercept™ Detect

Posted on 09/24/2015 in Blog Post, News, Press Releases

Pathway Genomics greatly respects and shares the FDA’s concerns about patient safety. We have received a letter from FDA, dated September 21, 2015, requesting certain information regarding the Pathway Genomics CancerIntercept™ Detect testing service.  We are carefully considering the concerns of the FDA as stated in their letter, and we will be responding to that letter.  We assure that there is physician involvement in the ordering, review and follow-up of CancerIntercept™ testing.  We believe that CancerIntercept™ Detect is a  laboratory developed test and, as a CLIA and CAP certified clinical laboratory, we are offering it as such.  While Pathway Genomics is involved in educating and marketing the tests to physicians and consumers, we do not believe this is a direct-to-consumer model. We believe we have performed appropriate validation of the test as a laboratory developed test, and we are in the process of performing additional studies.

Pathway Genomics Launches First Liquid Biopsy Test To Detect Cancer-Associated Mutations In High-Risk Patients

Posted on 09/09/2015 in Blog Post, News

CancerIntercept-Detect-Monitor_header_
SAN DIEGO – Sept. 10, 2015 – Pathway Genomics, a global precision medical diagnostics company, announced the launch of CancerInterceptTM, its first liquid biopsy, a non-invasive screening test designed for early cancer detection and monitoring, for as low as $299. Click to Tweet  

Former Administrator of the U.S. Small Business Administration Hector Barreto Joins Pathway Genomics’ Strategic Advisory Board

Posted on 08/17/2015 in Blog Post, News, Press Releases

Former Administrator of the U.S. Small Business Administration Hector Barreto Joins Pathway Genomics’ Strategic Advisory Board

Hector_Barreto_258x305
San Diego, CA – August 18, 2015Pathway Genomics, a global precision medical diagnostics company with mobile health applications designed to empower physicians and their patients to take control of their health and wellness, has announced today that Hector Barreto, the 21st Administrator of the U.S. Small Business Administration, has joined the Company’s Strategic Advisory Board. Click to Tweet  

Pathway Genomics Launches $99 Pathway Fit Genetic Test For a Limited Time

Posted on 08/06/2015 in Blog Post, Press Releases

PR_PathwayFit-$99

Pathway Genomics Launches $99 Pathway Fit Genetic Test For a Limited Time

San Diego, CA – August 6, 2015Pathway Genomics, a global precision medical diagnostics company with mobile health applications designed to empower physicians and their patients to take control of their health and wellness, announced today the launch of a limited time pricing of $99 for the Pathway Fit® genetic test. Click to Tweet  

Pathway Genomics Adds Digital Health Entrepreneur Paul Sonnier To Strategic Advisory Board

Posted on 07/08/2015 in Blog Post, Press Releases, Uncategorized

Paul-Sonnier-258x388
San Diego, CA – July 9, 2015Pathway Genomics Corporation, a global precision medicine company with mobile solutions for clinical laboratory testing to empower physicians and their patients to take control of their health and wellness, announced today that Paul Sonnier, digital health advocate and social entrepreneur, is joining the company’s Strategic Advisory Board. Click to Tweet  

Former United States Secretary of Commerce Barbara Franklin Joins Pathway Genomics’ Board of Directors

Posted on 06/15/2015 in Blog Post, Press Releases

Barbara Franklin
Former United States Secretary of Commerce Barbara Franklin Joins Pathway Genomics’ Board of Directors   San Diego, CA – June 16, 2015Pathway Genomics Corporation, a global precision medicine company with mobile health solutions for clinical laboratory testing to empower physicians and their patients to take control of their health and wellness, announced today that the 29th U.S. Secretary of Commerce, The Honorable Barbara Franklin is joining the company’s Board of Directors. Click to Tweet  

Twitter Stream


Recent Posts

Search Posts